Literature DB >> 22700481

Underlying cause discovered for a prior idiopathic AMI.

R Godfrey1, R O'Hanlon, M Wilson, J Buckley, S Sharma, G Whyte.   

Abstract

The authors previously reported on an active, young male with normal coronaries who sustained an acute myocardial infarction (AMI). The acute cause was a coronary thrombus; however, the cause of this thrombus and a definitive diagnosis remained elusive for 18 months until a new series of events, including symptoms of breathlessness, dizziness and collapse led to acute hospital admission. CT scan revealed numerous deep venous thromboses in the right leg and bilateral pulmonary emboli (PE). Acute pharmacological thrombolysis eliminated breathlessness and significantly reduced the risk of mortality. Clinical consensus suggests a coagulopathy, requiring indefinite treatment with Warfarin. In young individuals presenting with AMI, lifestyle, personal, family and clinical history should be considered and coronary artery disease should not be assumed until further tests have eliminated coagulopathy. In those presenting with breathlessness and a history which includes AMI, a CT scan is indicated to eliminate concerns of venous thromboembolism generally and PE specifically where untreated survival times are short.

Entities:  

Mesh:

Year:  2011        PMID: 22700481      PMCID: PMC3070342          DOI: 10.1136/bcr.02.2011.3799

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Pulseless electrical activity with witnessed arrest as a predictor of sudden death from massive pulmonary embolism in outpatients.

Authors:  D M Courtney; H C Sasser; C L Pincus; J A Kline
Journal:  Resuscitation       Date:  2001-06       Impact factor: 5.262

2.  British Thoracic Society guidelines for the management of suspected acute pulmonary embolism.

Authors: 
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

Review 3.  Myocardial infarction with angiographically normal coronary arteries.

Authors:  B Chandrasekaran; A S Kurbaan
Journal:  J R Soc Med       Date:  2002-08       Impact factor: 5.344

4.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

5.  Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?

Authors:  D A Sandler; J F Martin
Journal:  J R Soc Med       Date:  1989-04       Impact factor: 5.344

6.  Acute myocardial infarction in the presence of normal coronaries and the absence of risk factors in a young, lifelong regular exerciser.

Authors:  Gregory Whyte; Richard Godfrey; Rory O'Hanlon; Mathew Wilson; John Buckley; Sanjay Sharma
Journal:  BMJ Case Rep       Date:  2009-05-25

7.  Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography.

Authors:  M Turiel; S Muzzupappa; B Gottardi; C Crema; P Sarzi-Puttini; E Rossi
Journal:  Lupus       Date:  2000       Impact factor: 2.911

Review 8.  Risk factors for venous thromboembolism.

Authors:  Frederick A Anderson; Frederick A Spencer
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

9.  Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting.

Authors:  Liam Smeeth; Claire Cook; Sara Thomas; Andrew J Hall; Richard Hubbard; Patrick Vallance
Journal:  Lancet       Date:  2006-04-01       Impact factor: 79.321

  9 in total
  1 in total

1.  The effect of high-intensity aerobic interval training on postinfarction left ventricular remodelling.

Authors:  Richard Godfrey; Thomas Theologou; Santo Dellegrottaglie; Sukumaran Binukrishnan; Jay Wright; Gregory Whyte; Georgina Ellison
Journal:  BMJ Case Rep       Date:  2013-02-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.